DAVIS, Calif., May 16, 2014 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (MBI) (Nasdaq:MBII) today announced that it has filed a registration statement with the Securities and Exchange Commission for a public offering of up to $35 million of common stock to be sold by MBI and selling stockholders, including shares MBI may sell to the underwriters under a 30-day option to purchase additional shares.
MBI currently intends to use the net proceeds it receives from the proposed offering for working capital required to accelerate the commercial adoption of its existing products, to accelerate the development of its product pipeline and to expand its network of strategic relationships, for capital expenditures, including to purchase equipment to facilitate its research and development efforts and to accelerate completion of the manufacturing facility it acquired in July 2012, and for general corporate purposes, such as acquiring complementary businesses, products or technologies.
The offering is subject to market and other conditions, including the effectiveness of the registration statement under the Securities Act of 1933.
Jefferies LLC and Piper Jaffray & Co. will act as lead joint book-running managers for the offering.
A copy of the prospectus related to the offering, when available, can be obtained from Jefferies LLC, Equity Syndicate Prospectus Department, at 520 Madison Avenue, New York, New York, 10022, or by calling (877) 547-6340, or by emailing Prospectus_Department@Jefferies.com, and from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by calling (800) 747-3924 or by emailing firstname.lastname@example.org.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
CONTACT: Investor Contact
The Blueshirt GroupDavid Niederman
Source: Marrone Bio Innovations